The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death
Open accessAbstract
The present study examined the expression and role of the thiazolidinedione (TZD)-activated transcription factor, peroxisome proliferator-activated receptor gamma (PPARgamma), in human bladder cancers. In situ hybridization shows that PPARgamma mRNA is highly expressed in all human transitional epithelial cell cancers (TCCa's) studied (n=11). PPARgamma was also expressed in five TCCa cell lines as determined by RNase protection assays and immunoblot. Retinoid X receptor alpha (RXRalpha), a 9-cis-retinoic acid stimulated (9-cis-RA) heterodimeric partner of PPARgamma, was also co-expressed in all TCCa tissues and cell lines. Treatment of the T24 bladder cancer cells with the TZD PPARgamma agonist troglitazone, dramatically inhibited 3H-thymidine incorporation and induced cell death. Addition of the RXRalpha ligands, 9-cis-RA or LG100268, sensitized T24 bladder cancer cells to the lethal effect of troglitazone and two other PPAR- activators, ciglitazone and 15-deoxy-delta(12,14)-PGJ2 (15dPGJ(2)). Troglitazone treatment increased expression of two cyclin-dependent kinase inhibitors, p21(WAF1/CIP1) and p16(INK4), and reduced cyclin D1 expression, consistent with G1 arrest. Troglitazone also induced an endogenous PPARgamma target gene in T24 cells, adipocyte-type fatty acid binding protein (A-FABP), the expression of which correlates with bladder cancer differentiation. In situ hybridization shows that A-FABP expression is localized to normal uroepithelial cells as well as some TCCa's. Taken together, these results demonstrate that PPARgamma is expressed in human TCCa where it may play a role in regulating TCCa differentiation and survival, thereby providing a potential target for therapy of uroepithelial cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Cited by
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Self-citationNeumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284
Azoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., & Suissa, S. (2012) · BMJ · doi:10.1136/bmj.e3645 · Cited by 270
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
Metadata
- Authors
- Guan, Y.-F., Zhang, Y.-H., Breyer, R. M., Davis, L., & Breyer, M. D.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 1999-10
- Volume
- 1
- Issue
- 4
- Pages
- 330-339
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2082597621
- Cited by
- 173
- References
- 1
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death. https://app.cochat.ai/papers/10.1038/sj.neo.7900050
- The paper
- Guan, Y.-F., Zhang, Y.-H., Breyer, R. M., Davis, L., & Breyer, M. D. (1999). Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death. Neoplasia. https://doi.org/10.1038/sj.neo.7900050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.